June 12, 2009 – Naviscan Inc. announced that it has issued a non-exclusive licensing agreement with an undisclosed imaging company for intellectual property enabling Naviscan's Stereo Navigator PEM-guided biopsy accessory, and will be demonstrating the technology at the SNM's 56th Annual Meeting Annual Meeting, Toronto, June 13 - 16, 2009, in booth 638.
This is the second licensing agreement based on Naviscan's robust intellectual property portfolio and reinforces Naviscan's leadership position in molecular breast imaging (MBI). The company is currently negotiating licensing agreements with other diagnostic imaging companies and expects these agreements to be signed as early as the third quarter of 2009.
"This licensing agreement further validates the attractiveness of our patent portfolio to leading companies in the medical imaging sector," said Paul Mirabella, Chairman and CEO of Naviscan, Inc. "It also illustrates how we are leveraging our intellectual property and capitalizing on our innovative technology to create additional value to our share holders."
The new licensing agreement covers the use of Stereo Navigator a medical method and apparatus for the localization and biopsy of lesions. This patent enables PET scanners and gamma cameras to obtain emission data, locate the abnormal tissue and process the data to best guide a biopsy needle to acquire a sample of the abnormal tissue. The previous licensing agreement concerned a method and apparatus patent enabling the immobilization and compression of a body part for the purposes of collecting PET or gamma emission data in an effort to create a physiological image of the body part.
"Naviscan currently has four other patents pending," continued Mirabella. "Our expanding patent portfolio continues to strengthen our technology leadership role while creating opportunities to build strategic partnerships, monetize our intellectual properties and, in turn, increase the company's valuation."
For more information: www.naviscan.com
April 18, 2024 
